IP Library Granted Patent US 9,155,799
Granted Patent B2
US 9,155,799 · App. 13/815,736 · Granted Oct 13, 2015

Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent

Inventor: Thomas J. Koob (Kennesaw, GA)
Assignee: MiMedx Group, Inc.
A61K47/48246A61K8/19A61K8/65A61K9/0024A61K33/38A61K38/39A61K47/42A61L27/24A61L27/54A61Q17/005A61K2800/51A61L2300/104A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,799
App. No.
13/815,736
Granted
Oct 13, 2015
Kind
B2
Abstract

The disclosure describes collagen constructs comprising antimicrobial agents and related methods.

Claims (10)

1. An antimicrobial cross-linked collagen construct comprising: a cross-linked collagen comprising collagen and one or more cross-linking agents and an antimicrobial amount of silver incorporated into the construct, wherein at least a portion of the silver is incorporated into the cross-linked collagen by chelation, and at least one of the cross-linking agents is nordihydroguaiaretic acid (NDGA).

2. The construct of claim 1 , wherein the silver comprises ionic silver selected from the group consisting of silver (I) and/or silver (II).

3. The construct of claim 2 wherein the ionic silver comprises silver chloride, silver phosphate, silver sulfate, silver acetate, silver nitrate, silver fluoride, silver iodide, silver lactate, silver benzoate, silver bromide, silver carbonate, silver citrate, silver iodate, silver laurate, silver oxide, silver palmitate, silver protein, silver imidazolate, arglaes, colloidal silver, silver crystals.

4. The construct of claim 1 , wherein the silver incorporated into the construct is present in an amount of between about 0.1% to about 30%.

5. The construct of claim 1 , wherein some or all of the antimicrobial amount of silver is released in vivo in contact with an aqueous medium.

6. The construct of claim 1 , wherein the antimicrobial cross-linked collagen construct provides a sustained release of silver, wherein the sustained release comprises a plurality of release rates including an immediate release, an intermediate release, an extended release or any combination of release rates thereof.

7. The construct of claim 6 , wherein an effective amount of silver is released from about 1 minute to about 60 days, or any range therein.

8. A method of manufacturing an antimicrobial cross-linked collagen construct comprising cross-linked collagen and an antimicrobial amount of silver, wherein the silver is incorporated into the construct at least in part through the cross-linking agent, the method comprising contacting the cross-linked collagen with silver to provide the antimicrobial cross-linked collagen construct, wherein the cross-linked collagen comprises collagen and one or more cross-linking agents, and at least one of the cross-linking agents is NDGA.

9. A method of treating a subject suffering from a microbial infection, the method comprising administering an antimicrobial cross-linked collagen construct in the subject, wherein the construct comprises (a) cross-linked collagen comprising collagen and one or more cross-linking agents and (b) silver incorporated therein, to release an effective amount of silver into the subject, and wherein at least one of the cross-linking agents is NDGA.

10. The method of claim 9 wherein the effective amount of silver is released from the construct as ionic silver and/or as non-ionic silver in a plurality of in vivo release rates.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2024
From: HAYFIN SERVICES LLP
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 066493/0322 →
SECURITY INTEREST Recorded Jan 25, 2024
From: MIMEDX GROUP, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 066250/0132 →
PATENT SECURITY AGREEMENT Recorded Jul 2, 2020
From: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 053121/0833 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 054075/0687 →
SECURITY INTEREST Recorded Jun 11, 2019
From: MIMEDX GROUP, INC.
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 049426/0863 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2019
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: MIMEDX GROUP, INC.
Reel/Frame 048121/0835 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Oct 15, 2015
From: MIMEDX GROUP, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036872/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2013
From: KOOB, THOMAS J.
To: MIMEDX GROUP, INC.
Reel/Frame 031095/0158 →
Continuity (2)
Provisional Application 61728200 · Nov 19, 2012
Related Publication 20140142025A1 · May 22, 2014